Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

PHASE1RecruitingINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Enasidenib

Given PO

DRUG

Gilteritinib

Given PO

DRUG

Ivosidenib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER